- The disease
- Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer. It typically arises in the setting of chronic liver disease or cirrhosis and is often diagnosed at an advanced stage, limiting surgical options. Systemic treatment options exist but outcomes remain poor for many patients with advanced disease.
- What the asset is trying to do
- GPC3-iNKT is an allogeneic cell therapy that engineers invariant natural killer T (iNKT) cells to carry a chimeric antigen receptor (CAR) directed at glypican-3 (GPC3), a protein expressed on the surface of HCC cells. Because the cells are allogeneic, they are manufactured from a donor rather than the individual patient, which allows for an off-the-shelf supply model. Arovella holds an exclusive option to license the technology from Baylor College of Medicine. The asset is currently at preclinical stage.
- What the trial is measuring, and why it matters
- No clinical trial has been registered for GPC3-iNKT in hepatocellular carcinoma. Endpoints, patient population, and trial design are therefore not yet publicly defined for this indication.
- Efficacy benchmarks in this setting
- In HCC, the approved systemic therapies sorafenib and lenvatinib serve as common reference points. In the Phase 3 REFLECT trial, lenvatinib achieved an objective response rate (ORR) of 24.1% versus 9.2% for sorafenib (per Kudo et al, Lancet 2018). Atezolizumab plus bevacizumab (IMbrave150 trial) achieved an ORR of 27.3% by independent review (per Finn et al, NEJM 2020). No clinical efficacy data for GPC3-iNKT in HCC are yet available given the asset's preclinical status; early preclinical figures, if reported, would not be statistically comparable to the above approved-therapy outcomes.
- Commercial context
- No cell therapy targeting GPC3 is currently approved for HCC in any major market. Arovella's access to GPC3-iNKT is structured as an exclusive option from Baylor College of Medicine; the financial terms of that option have not been publicly disclosed. GPC3-iNKT in HCC appears to be a pipeline asset distinct from ALA-101, which targets CD19 and has received TGA clearance under the Clinical Trial Notification (CTN) scheme for a lymphoma and leukaemia study (per ASX announcement, 2026-03-15).